Selected News & Events
Stealth BioTherapeutics Announces Positive End-of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration
Stealth BioTherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide for the Treatment of Barth Syndrome in Europe and Key Global Territories
Stealth BioTherapeutics Presents at the 2023 JMP Securities Life Sciences Conference
Stealth BioTherapeutics to Present Overview of Elamipretide Clinical Development Program in Barth Syndrome at the 2023 American College of Medical Genetics Meeting
Events Calendar
No events listed at this time.
@StealthBT on Twitter
Twitter feed is not available at the moment.
Contact Us
Stealth BioTherapeutics
275 Grove Street, Suite 3-107
Newton, MA 02466
(617) 600-6888
info@stealthbt.com